title: Current application of β-tricalcium phosphate composites in orthopaedics.
abstract: Presently, bioceramic materials have been extensively used in spinal surgery as bone grafts; however, there are some limitations for bioceramic materials. Calcium sulfate is rapidly absorbed in vivo, the degradation of which often occurs prior to the formation of new bones. Hydroxyapatite (HA) is hardly absorbed, which blocks the formation of new bones and remodeling, and results in poor local stability or permanent stress concentration. Only β-tricalcium phosphate (β-TCP) is relatively balanced between scaffold absorption and bone formation. And it is a good biodegradable ceramic material that could supply a large quantity of calcium ion and sulfate ion as well as scaffold structure for bone regeneration. However, the problem of single β-TCP is lack of osteoinductivity and osteogenicity, which restricts its application. Therefore β-TCP composite materials have been used in the field of orthopaedics in recent decades, which fully use excellent properties of other bone repairing materials, such as biodegradability, osteoinductivity, osteogenicity and osteoconductivity. These materials make up for the deficiencies of single β-TCP and endow β-TCP with more biological and physical properties.
authors.affiliation: Center for Medical Device Evaluation of State Food and Drug Administration, Beijing, China. sfdacmd@sina.com
authors.forename: Bin
authors.initials: B
authors.lastname: Liu
authors.forename: Deng-xing
authors.initials: DX
authors.lastname: Lun
mesh_terms: D001672:Biocompatible Materials / Q000737:chemistry* / Q000627:therapeutic use; D001853:Bone Marrow / Q000737:chemistry; D055396:Bone Morphogenetic Protein 2 / Q000737:chemistry / Q000627:therapeutic use; D002130:Calcium Phosphates / Q000737:chemistry* / Q000627:therapeutic use; D017886:Durapatite / Q000737:chemistry / Q000627:therapeutic use; D026122:Factor XIIIa / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D007477:Ions / Q000737:chemistry / Q000627:therapeutic use; D008670:Metals / Q000737:chemistry / Q000627:therapeutic use; D019637:Orthopedic Procedures / Q000379:methods*; D009985:Orthopedics / Q000379:methods*; D053657:Platelet-Rich Plasma / Q000737:chemistry; D011091:Polyesters / Q000737:chemistry / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000737:chemistry / Q000627:therapeutic use; D023822:Tissue Engineering / Q000379:methods*; D016212:Transforming Growth Factor beta / Q000737:chemistry / Q000627:therapeutic use
chemical_list: D001672:Biocompatible Materials; D055396:Bone Morphogenetic Protein 2; D002130:Calcium Phosphates; D007477:Ions; D008670:Metals; D011091:Polyesters; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C485817:beta-tricalcium phosphate; C499469:recombinant human bone morphogenetic protein-2; C016240:polycaprolactone; D017886:Durapatite; D026122:Factor XIIIa